The press releases published by TME Pharma (formerly NOXXON Pharma) and contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. TME Pharma disavows any obligation to update the information contained in such press releases after the date of their issuance.
Filter: NOX-A12 (olaptesed) | NOX-E36 (emapticap) | all
| Date | Title | Download | ||
| 2024, September 30 06:00 p.m. | TME Pharma announces appointment of Alexandra Glucksmann to supervisory board |  |  | |
| 2024, September 27 08:00 a.m. | TME Pharma provides results of third exercise of Warrants Z | | | |
| 2024, September 19 08:00 a.m. | TME Pharma announces acceptance of the NCI’s abstract on NOX-A12 in glioblastoma for presentation at the SNO 2024 Annual Meeting | | | |
| 2024, September 16 08:00 a.m. | TME Pharma announces oral presentation at ESMO Congress 2024 with updated results from NOX-A12 GLORIA Phase 1/2 trial in glioblastoma | | | |
| 2024, August 27 06:00 p.m. | TME Pharma announces convocation of an extraordinary general meeting of shareholders | | | |
| 2024, August 12 07:00 p.m. | TME Pharma provides update on resources allocated to the liquidity contract with Invest Securities | | | |
| 2024, July 31 06:00 p.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2024, July 22 08:00 a.m. | TME Pharma announces strategic plan to externalize and monetize second clinical stage asset NOX-E36 | | | |
| 2024, July 17 08:00 a.m. | TME Pharma announces oral presentation of NOX-A12 GLORIA Phase 1/2 trial in glioblastoma at ESMO Congress 2024 | | | |
| 2024, July 09 06:00 p.m. | CEO Message H1 2024 | | | |
| 2024, June 28 08:00 a.m. | TME Pharma provides results of second exercise of Warrants Z | | | |
| 2024, June 27 06:00 p.m. | TME Pharma announces appointment of Lee Schalop to supervisory board and approval of all resolutions submitted to the 2024 annual general meeting of shareholders | | | |
| 2024, June 18 08:00 a.m. | TME Pharma announces results of successful capital increase with €2.35 million raised | | | |
| 2024, June 17 05:45 p.m. | TME Pharma announces a financing guarantee agreement and the launch of capital increase of minimum 2.2 million euros | | | |
| 2024, June 17 05:30 p.m. | TME Pharma announces publication in Nature Communications of biomarker data from NOX-A12 GLORIA Phase 1/2 trial in glioblastoma | | | |
| 2024, May 27 08:00 a.m. | TME Pharma announces convocation of the 2024 annual general meeting of shareholders | | | |
| 2024, April 25 06:00 p.m. | TME Pharma publishes 2023 financial results and provides operating update | | | |
| 2024, April 23 08:00 a.m. | TME Pharma announces 33% of patients receiving NOX-A12 in combination with bevacizumab and radiotherapy achieve two-year survival in GLORIA Phase 1/2 trial in brain cancer | | | |
| 2024, April 02 08:00 p.m. | TME Pharma receives US FDA Fast Track designation for lead asset NOX-A12 in brain cancer | | | |
| 2024, March 28 08:00 a.m. | TME Pharma provides results of first exercise of Warrants Z | | | |
| 2024, March 05 08:00 a.m. | TME Pharma announces FDA clearance of Investigational New Drug (IND) application for NOX-A12 Phase 2 trial in brain cancer | | | |
| 2024, February 23 08:00 a.m. | TME Pharma provides results of final exercise of Warrants Y: Additional €854k raised and extension of cash runway from May into July 2024 | | | |
| 2024, February 09 08:00 a.m. | TME Pharma announces the end of the convertible debt program with the successful €1.48 million financing intended for buyback of all outstanding convertible debt | | | |
| 2024, February 02 08:00 a.m. | TME Pharma announces final median overall survival data reaching 19.9 months for NOX-A12 combination regimen in GLORIA brain cancer trial and survival rate 10-fold greater than standard of care | | | |
| 2024, January 31 06:00 p.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2024, January 23 06:00 p.m. | TME Pharma provides update on number of outstanding shares and warrants following first Warrant Y exercise period | | | |
| 2024, January 09 06:00 p.m. | TME Pharma announces successful advice meeting with US Food and Drug Administration on NOX-A12 development in brain cancer | | | |
| 2023, December 20 08:00 a.m. | TME Pharma announces further improvement in median overall survival at 19 months follow-up in GLORIA brain cancer trial | | | |
| 2023, December 14 08:00 a.m. | TME Pharma announces results of successful capital increase with preferential subscription rights for €2.7 million | | | |
| 2023, November 28 08:00 a.m. | TME Pharma announces the initiation of the listing of preferential subscription rights for fully guaranteed €2.7 million capital increase | | | |
| 2023, November 24 06:00 p.m. | TME Pharma launches fully guaranteed €2.7 million preferential rights issue with warrants attached combined with buyback of convertible debt | | | |
| 2023, November 18 08:00 a.m. | TME Pharma announces additional data from NOX-A12 combination regimen in brain cancer presented at SNO 2023 Annual Meeting | | | |
| 2023, October 27 06:00 p.m. | TME Pharma reports H1 2023 financial results and provides business update | | | |
| 2023, October 20 08:00 a.m. | TME Pharma announces further improvement in overall survival at 18 months to 67% for NOX-A12 combination regimen in brain cancer | | | |
| 2023, October 17 07:00 p.m. | TME Pharma reports on end of six-month lock-up period of shares and convertible bonds following the April 2023 transaction | | | |
| 2023, October 16 08:00 a.m. | TME Pharma announces publication of ESMO Congress 2023 abstract on the ongoing NOX-A12 GLORIA Phase 1/2 trial in glioblastoma | | | |
| 2023, October 10 08:00 a.m. | TME Pharma provides positive update on 18-month survival for NOX-A12 combination regimen in brain cancer and provides strategic update including decision to engage with US FDA | | | |
| 2023, September 22 08:00 a.m. | TME Pharma announces selection of two clinical abstracts on the ongoing NOX-A12 GLORIA Phase 1/2 trial in glioblastoma for presentation at ESMO 2023 congress and SNO 2023 Annual Meeting | | | |
| 2023, September 13 08:00 a.m. | NOX-A12 combination regimen with bevacizumab: 17-month survival rate exceeds all relevant competitor treatments against most severe form of adult brain cancer | | | |
| 2023, July 20 06:00 p.m. | Half-yearly report on the liquidity contract with invest securities | | | |
| 2023, July 13 08:00 a.m. | TME Pharma provides positive data update on best response to therapy with first complete response in GLORIA trial in glioblastoma, bringing 50% of patients in expansion arm to complete or near-complete response | | | |
| 2023, June 30 06:00 p.m. | TME Pharma provides results of its 2023 annual general meeting of shareholders and announces the resumption of the liquidity contract | | | |
| 2023, June 28 08:00 a.m. | TME Pharma announces positive 15-month survival data from GLORIA expansion arm evaluating NOX-A12 in combination with radiotherapy and bevacizumab in glioblastoma | | | |
| 2023, June 15 06:00 p.m. | TME Pharma receives Investigational New Drug (IND) approval for NOX-A12 from the US FDA | | | |
| 2023, May 30 08:00 a.m. | TME Pharma announces convocation of the 2023 annual general meeting of shareholders | | | |
| 2023, May 26 08:00 a.m. | TME Pharma announces publication of ASCO 2023 abstract disclosing new biomarker data from NOX-A12 GLORIA Phase 1/2 trial in glioblastoma | | | |
| 2023, May 25 06:00 p.m. | TME Pharma provides positive clinical update and 14-month survival data from GLORIA expansion arm evaluating NOX-A12 in combination with radiotherapy and bevacizumab in glioblastoma | | | |
| 2023, April 27 08:00 a.m. | TME Pharma announces new data from NOX-A12 GLORIA Phase 1/2 study in glioblastoma to be presented at ASCO annual meeting in June 2023 | | | |
| 2023, April 24 06:00 p.m. | TME Pharma publishes audited Annual Report 2022 | | | |
| 2023, April 18 08:00 p.m. | TME Pharma announces successful €2 million financing and the end of the convertible bond program with a lock-up of new shares and lock-up of bond conversions extending financial runway into December 2023 | | | |
| 2023, April 18 06:00 p.m. | TME Pharma publishes unaudited financial results for fiscal year 2022 | | | |
| 2023, March 29 08:45 a.m. | TME Pharma announces temporary suspension of liquidity contract with Invest Securities | | | |
| 2023, March 27 08:00 a.m. | TME Pharma announces 83% of glioblastoma patients still alive after 12 months on study (median) in GLORIA expansion arm evaluating NOX-A12 in combination with radiotherapy and bevacizumab | | | |
| 2023, February 24 08:00 a.m. | TME Pharma CEO message | | | |
| 2023, January 30 06:00 p.m. | TME Pharma announces results of the extraordinary general meeting of shareholders | | | |
| 2023, January 23 08:00 a.m. | TME Pharma provides clinical update on the GLORIA expansion arm testing NOX-A12 in combination with radiotherapy and bevacizumab in patients with glioblastoma | | | |
| 2023, January 20 06:00 p.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2022, December 30 06:00 p.m. | TME Pharma announces convocation of an extraordinary general meeting of shareholders | | | |
| 2022, November 28 06:00 p.m. | TME Pharma announces the resignation of its Chief Financial Officer Bryan Jennings | | | |
| 2022, November 19 01:30 a.m. | Positive updated interim results from NOX-A12 GLORIA Phase 1/2 in brain cancer presented at the Society for Neuro-Oncology 2022 Annual Meeting | | | |
| 2022, November 14 08:00 a.m. | TME Pharma to host key opinion leader webinar | | | |
| 2022, November 11 01:00 p.m. | TME Pharma announces publication of abstract disclosing positive interim results from bevacizumab expansion arm of NOX-A12 GLORIA Phase 1/2 brain cancer clinical trial additional and updated data to be presented during SNO 2022 Annual Meeting on Nov 18, 2022 | | | |
| 2022, October 26 07:00 p.m. | TME Pharma reports H1 2022 financial results and provides business update | | | |
| 2022, September 20 06:00 p.m. | TME Pharma announces upcoming presentation at the Society for Neuro-Oncology Annual Meeting 2022 | | | |
| 2022, August 26 08:00 a.m. | Safety confirmed of NOX-A12 and pembrolizumab combination in GLORIA Phase 1/2 brain cancer study | | | |
| 2022, August 03 08:00 a.m. | TME Pharma announces enrollment of first patient in pembrolizumab expansion arm of NOX-A12 GLORIA Phase 1/2 brain cancer clinical trial | | | |
| 2022, July 27 07:00 p.m. | TME Pharma announces completion of share consolidation | | | |
| 2022, July 15 06:00 p.m. | TME Pharma announces €3.24 million financing under agreement with Atlas | | | |
| 2022, July 15 08:00 a.m. | NOXXON Pharma announces name change to “TME Pharma” and new trading symbol | | | |
| 2022, July 12 06:00 p.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2022, July 12 06:00 p.m. | NOXXON announces changes to its supervisory board | |  | |
| 2022, June 29 06:00 p.m. | NOXXON provides results of its 2022 annual general meeting of shareholders | | | |
| 2022, June 23 08:00 a.m. | NOXXON announces updated development strategy following strong clinical benefit observed with NOX-A12 in combination with radiotherapy and bevacizumab in brain cancer | | | |
| 2022, June 23 08:00 a.m. | NOXXON announces corporate action to start the parity period | | | |
| 2022, June 13 08:00 a.m. | NOXXON enters into collaboration with US National Cancer Institute to characterize effects of lead compounds on brain tumors | | | |
| 2022, June 05 03:00 p.m. | NOXXON presents full top-line results from NOX-A12 Phase 1/2 GLORIA trial in glioblastoma at the 2022 ASCO Annual Meeting | | | |
| 2022, June 01 08:00 a.m. | NOXXON to host key opinion leader webinar on GLORIA study top-line results of NOX-A12 and radiotherapy combination in first-line glioblastoma | | | |
| 2022, May 30 08:00 a.m. | NOXXON announces convocation of the 2022 annual general meeting of shareholders | | | |
| 2022, May 26 11:00 p.m. | NOXXON announces presentation of NOX-A12 Phase 1/2 data in glioblastoma at the 2022 ASCO Annual Meeting and invitation to a dedicated KOL event | | | |
| 2022, May 19 08:00 a.m. | NOXXON amends equity-linked facility with Atlas | | | |
| 2022, May 16 06:00 p.m. | NOXXON announces results of the extraordinary general meeting of shareholders | | | |
| 2022, May 11 08:00 a.m. | NOXXON appoints leading brain cancer experts to scientific advisory board | | | |
| 2022, April 22 06:00 p.m. | NOXXON reports 2021 financial results | | | |
| 2022, April 21 06:00 p.m. | NOXXON announces €2.375 million financing under agreement with Atlas | | | |
| 2022, April 14 06:00 p.m. | NOXXON announces convocation of an Extraordinary General Meeting of shareholders | | | |
| 2022, April 06 08:00 a.m. | Top-line results from NOXXONs NOX-A12 Phase 1/2 GLORIA trial in brain cancer to be presented during 2022 ASCO Annual Meeting | | | |
| 2022, March 24 08:00 a.m. | NOXXON announces top-line data of Phase 1/2 GLORIA study with NOX-A12 in partially resected or biopsy-only MGMT-unmethylated newly-diagnosed glioblastoma patients | | | |
| 2022, February 10 08:00 a.m. | NOXXON to participate in partnering and investor conferences in February and March 2022 | | | |
| 2022, January 28 06:00 p.m. | NOXXON announces €2.375 million financing under agreement with Atlas | | | |
| 2022, January 26 06:00 p.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2022, January 07 08:00 a.m. | NOXXON provides progress update on the expansion arms of the Phase 1/2 GLORIA trial with NOX-A12 in brain cancer patients | | | |
| 2022, January 05 07:30 p.m. | NOXXON provides update on evaluation of NOX-A12 in non-oncology indication by a leading international pharma company | | | |
| 2022, January 03 06:00 p.m. | Corrected press release: NOXXON secures €17 million expansion of equity-linked facility with Atlas to advance NOX-A12 in glioblastoma and pancreatic cancer programs | | | |
| 2021, December 29 06:00 p.m. | NOXXON secures Euro 17 million expansion of equity-linked facility with Atlas to advance NOX-A12 in glioblastoma and pancreatic cancer programs | | | |
| 2021, December 15 06:00 p.m. | NOXXON announces results of the extraordinary general meeting of shareholders | | | |
| 2021, December 15 08:00 a.m. | NOXXON to participate in banking and investor conferences in January and February 2022 | | | |
| 2021, December 07 08:00 a.m. | NOXXON announces enrolment of first patient in the expansion of the NOX-A12 Phase 1/2 trial in brain cancer | | | |
| 2021, December 02 08:00 a.m. | NOXXON summarizes essential points from Key Opinion Leader event on NOX-A12 & radiotherapy combination in brain cancer held on November 23, 2021 with Dr Frank A. Giordano | | | |
| 2021, November 22 08:00 a.m. | NOXXON: New Phase 1/2 data on NOX-A12 & radiotherapy combination in brain cancer presented at the Society for Neuro-Oncology Annual Meeting 2021 | | | |
| 2021, November 16 08:00 a.m. | NOXXON to host Key Opinion Leader webinar on NOX-A12 and radiotherapy combination: a differentiated and promising new approach to treating brain cancer | | | |
| 2021, November 15 08:00 a.m. | NOXXON announces convocation of an Extraordinary General Meeting of shareholders | | | |
| 2021, November 12 08:00 a.m. | New positive interim results from NOXXON’s Phase 1/2 GLORIA trial in brain cancer to be presented at the Society for Neuro-Oncology Annual Meeting 2021 | | | |
| 2021, November 09 08:00 a.m. | NOXXON to present at the third edition of Investir Day on November 23 in Paris, France | | | |
| 2021, November 03 08:00 a.m. | NOXXON provides update on timing for upcoming trials of NOX-A12 in pancreatic and brain cancer | | | |
| 2021, October 27 08:00 a.m. | Experienced financial executive, Bryan Jennings, joins NOXXON as CFO | | | |
| 2021, October 22 08:00 p.m. | NOXXON reports H1 2021 financial results and provides business update | | | |
| 2021, October 19 08:00 a.m. | NOXXON announces planned expansion of Phase 1/2 NOX-A12 brain cancer trial | | | |
| 2021, October 06 08:00 a.m. | NOXXON Pharma announces upcoming oral presentation at the Society for Neuro-Oncology Annual Meeting 2021 | | | |
| 2021, September 29 08:00 a.m. | NOXXON to participate in biotech and health-tech conferences in October 2021 | | | |
| 2021, September 22 08:00 a.m. | NOXXON enrolls last brain cancer patient in dose escalation portion of GLORIA study and confirms phase 1/2 read-out in Q1 2022 | | | |
| 2021, August 25 08:00 a.m. | NOXXON to attend the German Fall conference on September 6 & 7, 2021 | | | |
| 2021, August 05 08:00 a.m. | NOXXON provides update on NOX-A12 clinical programs | | | |
| 2021, July 28 08:00 a.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2021, July 21 06:00 p.m. | NOXXON Pharma enters second clinical collaboration with MSD to evaluate NOX-A12 in combination with KEYTRUDA (pembrolizumab) in upcoming Phase 2 pancreatic cancer study | | | |
| 2021, June 24 07:00 p.m. | NOXXON announces appointments of Susan Coles, Martine van Vugt and Gregory Weaver to supervisory board and provides results of its 2021 annual general shareholders meeting | | | |
| 2021, June 08 08:00 a.m. | CORRECTED PRESS RELEASE: NOXXON announces positive results from second cohort in Phase 1/2 NOX-A12 brain cancer trial | | | |
| 2021, June 01 06:00 p.m. | NOXXON announces manufacturing of NOX-A12 drug substance for future clinical trials and issuance of convertible bonds under financing agreement with Atlas | | | |
| 2021, June 01 08:00 a.m. | NOXXON announces positive results from second cohort in Phase 1/2 NOX-A12 brain cancer trial | | | |
| 2021, May 25 08:00 a.m. | NOXXON announces convocation of its hybrid 2021 annual general meeting of shareholders | | | |
| 2021, May 12 06:00 p.m. | NOXXON announces participation in 7th Annual Immuno-oncology Innovation Forum, May 18-20, 2021 | | | |
| 2021, May 10 06:00 p.m. | NOXXON announces Data Safety Monitoring Board validates NOX-A12 highest dose in Phase 1/2 brain cancer trial | | | |
| 2021, April 30 06:00 p.m. | NOXXON announces Euro 1.2M equity raise through conversion of warrants by Kreos Capital and other historical investors | | | |
| 2021, April 28 06:00 p.m. | NOXXON Pharma N.V. reports 2020 financial results | | | |
| 2021, April 14 06:00 p.m. | NOXXON successfully completes patient recruitment in Phase 1/2 brain cancer study of NOX-A12 plus radiotherapy | | | |
| 2021, March 12 08:00 a.m. | Data Safety Monitoring Board confirms safety and validates recruitment of last patients in final high-dose cohort of NOX-A12 in Phase 1/2 brain cancer study | | | |
| 2021, February 15 06:00 p.m. | NOXXON enrolls first patient in the high dose cohort of trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer | | | |
| 2021, February 08 06:00 p.m. | NOXXON appoints leading pancreatic cancer experts to Scientific Advisory Board | | | |
| 2021, February 01 06:00 p.m. | NOXXON appoints experienced cancer drug developer Dr. Jose Saro as chair of Scientific Advisory Board | | | |
| 2021, January 26 08:00 a.m. | NOXXON announces capital increase of Euro 6.4 million by private placement to further develop its business | | | |
| 2021, January 19 08:00 a.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2020, December 29 08:00 p.m. | NOXXON announces initiation of NOX-A12 manufacturing for future clinical studies | | | |
| 2020, November 09 08:00 a.m. | NOXXON announces that Data Safety Monitoring Board validates further NOX-A12 dose escalation in Phase 1/2 brain cancer study | | | |
| 2020, October 29 08:00 a.m. | NOXXON publishes interim 2020 results | | | |
| 2020, October 28 08:00 a.m. | NOXXON announces completion of 6-month therapy for low-dose cohort in Phase 1/2 brain cancer study of NOX-A12 plus radiotherapy | | | |
| 2020, October 20 08:00 a.m. | NOXXON announces three additional clinical centers to recruit patients for NOX-A12 brain cancer trial | | | |
| 2020, October 14 07:00 p.m. | NOXXON secures expanded capacity and improved conversion conditions for convertible bonds from Atlas | | | |
| 2020, October 14 08:00 a.m. | NOXXON announces successful completion of patient recruitment for second dose cohort in phase 1/2 brain cancer study of NOX-A12 plus radiotherapy | | | |
| 2020, September 17 09:00 a.m. | NOXXON presents final clinical data from phase 1/2 NOX-A12 / Keytruda combination trial in colorectal and pancreatic cancer at the ESMO virtual congress 2020 | | | |
| 2020, August 12 6:00 p.m. | NOXXON to present final clinical data from the NOX-A12 / Keytruda combination trial in colorectal and pancreatic cancer at the ESMO virtual congress 2020 | | | |
| 2020, July 24 8:00 a.m. | NOXXON announces first brain cancer patient from second dose cohort reaches 4 weeks of treatment with NOX-A12 combined with radiotherapy | | | |
| 2020, July 13 6:00 p.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2020, July 02 8:00 a.m. | NOXXON announces appointment of Oscar Izeboud to the supervisory board and provides results of the annual general shareholders meeting | | | |
| 2020, June 30 6:00 p.m. | NOXXON enrolls first patient in the second dose cohort of trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer | | | |
| 2020, June 16 6:00 p.m. | NOXXON announces capital increase of Euro 1.3 million by private placement to further develop its business | | | |
| 2020, June 12 6:00 p.m. | NOXXON announces issuance of tranches of Convertible Bonds under financing agreement with Atlas | | | |
| 2020, May 29 6:00 p.m. | NOXXON announces convocation of the hybrid annual general meeting of shareholders | | | |
| 2020, May 08 9:00 p.m. | NOXXON announces capital increase of EUR 5.5 million by private placement to further develop its business | | | |
| 2020, May 06 8:00 p.m. | NOXXON announces issuance of a tranche of Convertible Bonds under financing agreement with Atlas | | | |
| 2020, April 27 6:00 p.m. | NOXXON presents latest clinical data from the Phase 1/2 NOX-A12 / Keytruda combination trial in colorectal and pancreatic cancer at the AACR Virtual Annual Meeting 2020 | | | |
| 2020, April 24 8:00 a.m. | NOXXON announces that Data Safety Monitoring Board validates NOX-A12 dose escalation in Phase 1/2 brain cancer study | | | |
| 2020, April 23 8:00 a.m. | NOXXON secures financing of up to 14.2 million Euro through convertible bonds from Atlas | | | |
| 2020, April 22 8:00 a.m. | NOXXON Pharma N.V. reports 2019 financial results | | | |
| 2020, April 20 7:00 p.m. | NOXXON announces complete conversion of Acuitas warrants | | | |
| 2020, April 14 6:00 p.m. | NOXXON to present latest clinical data from the NOX-A12 / KEYTRUDA combination trial in colorectal and pancreatic cancer at the AACR Virtual Annual Meeting 2020 | | | |
| 2020, April 02 8:00 a.m. | NOXXON announces completion of patient recruitment for the first dose cohort in the phase 1/2 brain cancer study of NOX-A12 plus radiotherapy | | | |
| 2020, March 31 6:00 p.m. | NOXXON provides update on clinical trial recruitment and corporate operations during COVID-19 pandemic | | | |
| 2020, January 20 6:00 p.m. | NOXXON announces another capital increase of 0.5 million Euro through a private placement of shares | | | |
| 2020, January 16 6:00 p.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2020, January 14 8:00 a.m. | NOXXON announces a capital increase of 0.5 million Euro through a private placement of shares | | | |
| 2019, December 20 8:00 a.m. | NOXXON announces first brain cancer patient reaches 10 weeks of treatment with NOX-A12 plus radiotherapy | | | |
| 2019, October 24 6:00 p.m. | NOXXON publishes interim 2019 results | | | |
| 2019, October 16 8:00 a.m. | NOXXON enrolls first patient in the phase 1/2 clinical trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer | | | |
| 2019, September 29 12:00 p.m. | NOXXON presents latest clinical data from Phase 1/2 NOX-A12 / Keytruda combination trial at the ESMO congress | | | |
| 2019, September 18 8:00 a.m. | NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the ESMO congress | | | |
| 2019, September 12 6:00 p.m. | NOXXON initiates patient recruitment for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of brain cancer patients | | | |
| 2019, August 15 8:00 a.m. | NOXXON announces completion of EUR 1 million capital increase | | | |
| 2019, August 06 8:00 p.m. | NOXXON announces a capital increase of Euro 1 million through a private placement of shares without warrants | | | |
| 2019, July 22 8:00 p.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2019, July 19 8:30 p.m. | NOXXON raises amount of Euro 521 K in its rights issue | | | |
| 2019, June 27 8:00 a.m. | Results of NOXXON annual general shareholders meeting | | | |
| 2019, June 26 8:00 a.m. | NOXXON announces launch of capital increase right issue for an amount of up to Euro 3.9 M | | | |
| 2019, June 24 8:00 a.m. | NOXXON announces leading international pharma to evaluate NOX-A12 in new indication | | | |
| 2019, May 24 6:00 p.m. | NOXXON announces convocation of the annual general meeting of shareholders | | | |
| 2019, May 03 8:00 p.m. | NOXXON announces change within supervisory board | | | |
| 2019, April 12 7:00 p.m. | NOXXON Pharma N.V. reports 2018 financial results | | | |
| 2019, April 01 7:00 p.m. | NOXXON presents updated results from Phase 1/2 NOX-A12 / Keytruda combination trial at AACR 2019 | | | |
| 2019, February 28 7:00 p.m. | NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the 2019 AACR Annual Meeting | | | |
| 2019, February 27 6:00 p.m. | NOXXON files application for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of brain cancer | | | |
| 2019, February 18 8:00 a.m. | NOXXON publishes a shareholder letter | | | |
| 2019, February 01 8:00 a.m. | New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer | | | |
| 2019, January 14 6:00 p.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2019, January 04 8:00 a.m. | Results of NOXXON's extra-ordinary general meeting of shareholders | | | |
| 2018, December 20 8:00 a.m. | NOXXON announces participation in the East/West CEO Forum in San Francisco, in January 2019 | | | |
| 2018, December 14 12:30 p.m. | NOXXON announces key findings that NOX-A12 plus Keytruda induces an immune response and results in clinical benefit for patients | | | |
| 2018, December 13 8:00 p.m. | NOXXON announces trading halt on Euronext Growth Paris ahead of trial data publication at the ESMO Immuno-Oncology Congress | | | |
| 2018, December 10 8:00 a.m. | NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at ESMO immuno-oncology congress on December 13-16, 2018 | | | |
| 2018, December 03 0:01 a.m. | NOXXON announces convocation of an extra-ordinary general meeting of shareholders | | | |
| 2018, November 21 8:00 a.m. | NOXXON to launch NOX-A12 with radiotherapy clinical trial in patients with brain cancer | | | |
| 2018, November 16 8:00 a.m. | NOXXON announces EUR 6.2 million equity capital raise including US$ 5 million from US family office - Acuitas Capital, LLC | | | |
| 2018, October 26 8:00 a.m. | NOXXON to present top-line efficacy data from NOX-A12 / Keytruda combination trial in December as planned at ESMO Immuno-Oncology Conference | | | |
| 2018, October 23 6:00 p.m. | NOXXON to attend European investor and partnering conferences in November 2018 | | | |
| 2018, October 16 8:00 a.m. | NOXXON to attend the ESMO 2018 congress in Munich | | ||
| 2018, October 11 8:00 a.m. | NOXXON publishes interim 2018 results | | | |
| 2018, October 02 6:00 p.m. | NOXXON presents top-line data from NOX-A12 monotherapy part of ongoing metastatic colorectal and pancreatic cancer trial | | | |
| 2018, September 19 6:00 p.m. | NOXXON announces listing of convertible bonds and additional investment | | | |
| 2018, September 19 8:00 a.m. | NOXXON to present clinical trial data at Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 'Translating Science into Survival' | | | |
| 2018, September 03 8:00 a.m. | NOXXON announces completion of patient recruitment in ongoing NOX-A12 pancreatic and colorectal cancer trial | | | |
| 2018, August 14 8:00 a.m. | NOXXON raises additional funds via ODIRNANE bonds and extends timing to cancel investor's unilateral right to invest | | | |
| 2018, August 08 6:00 p.m. | NOXXON to host Key Opinion Leader event on novel treatment approaches for glioblastoma on September 4th, 2018 | | | |
| 2018, August 01 8:00 a.m. | NOXXON announces that it has secured additional financing | | | |
| 2018, July 16 6:00 p.m. | NOXXON announces amendment to loan agreements | | | |
| 2018, July 13 6:00 p.m. | Half-yearly report on the liquidity contract with invest securities | | | |
| 2018, July 03 8:00 a.m. | NOXXON issues tranche of ODIRNANE bonds | | | |
| 2018, June 28 8:00 p.m. | NOXXON provides update on patient recruitment in ongoing NOX-A12 pancreatic and colorectal cancer trial | | | |
| 2018, June 22 8:00 a.m. | Results of NOXXON annual general shareholders meeting | | | |
| 2018, June 15 8:00 a.m. | NOXXON announces that it has secured additional financing | | | |
| 2018, June 06 6:00 p.m. | NOXXON issues seventh tranche of ODIRNANE bonds | | | |
| 2018, May 29 8:00 a.m. | NOXXON provides clinical update prior to American Society of Clinical Oncology (ASCO) annual conference | | | |
| 2018, May 18 6:00 p.m. | NOXXON announces convocation of the annual general meeting of shareholders | | | |
| 2018, May 15 6:00 p.m. | NOXXON to present clinical trial update at BioEquity Europe | | | |
| 2018, April 30 9:00 p.m. | NOXXON PHARMA N.V. reports 2017 financial results | | | |
| 2018, April 26 8:00 a.m. | NOXXON publishes results of extraordinary shareholders meeting | | | |
| 2018, April 10 8:00 a.m. | NOXXON announces initiation of analyst coverage by Aurgalys | | | |
| 2018, March 22 9:00 p.m. | NOXXON announces convocation of an extra-ordinary general meeting of shareholders | | | |
| 2018, March 13 8:00 a.m. | NOXXON renegotiates ODIRNANE BSA financing agreement to remove unilateral option for investor to subscribe for tranches and to cancel existing warrents | | | |
| 2018, January 31 6.00 p.m. | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2018, January 23 8:00 a.m. | NOXXON issues fourth tranche of ODIRNANE bonds | | | |
| 2017, November 22 | NOXXON announces its participation in three European investor conferences in November and December 2017 | | | |
| 2017, November 21 | NOXXON issues third tranche of ODIRNANE bonds | | | |
| 2017, October 30 | NOXXON releases interim 2017 results | | | |
| 2017, October 11 | NOXXON Pharma réaffirme son éligibilité au PEA-PME pour 2017/2018 (French only) | | ||
| 2017, October 03 | NOXXON Publishes Preclinical Proof-Of-Concept Data for Lead Compound NOX-A12 in Combination with Checkpoint Inhibitors | | | |
| 2017, September 29 | NOXXON Supervisory Board elects experienced US and EU biotech veteran Don deBethizy chairman | | | |
| 2017, September 28 | NOXXON provides update on ongoing phase 1/2 clinical trial with lead program NOX-A12 | | | |
| 2017, September 26 | NOXXON announces its participation in two french investor conferences in October 2017 | | | |
| 2017, September 19 | NOXXON issues second tranche of ODIRNANE bonds | | | |
| 2017, August 25 | Half-yearly report on the liquidity contract with Invest Securities | | | |
| 2017, July 18 | NOXXON issues first tranche of ODIRNANE bonds | | | |
| 2017, July 11 | NOXXON Pharma announces prospectus publication and share transfer to the public offering compartment of the EuroNext Growth market | | | |
| 2017, July 04 | NOXXON announces first patients treated in phase I/II clinical trial of NOX-A12 combined with Keytruda in metastatic pancreatic and colorectal cancer | | | |
| 2017, June 29 | Results of NOXXON Annual General Meeting | | | |
| 2017, June 07 | NOXXON publishes Annual General Meeting Documents | | | |
| 2017, May 26 | NOXXON announces record date and date of annual general meeting | | | |
| 2017, May 16 | NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12/Keytruda phase 1/2 combination trial | | | |
| 2017, May 02 | NOXXON PHARMA SECURES A PRIVATE PLACEMENT OF EUR 1 MILLION AND ADDITIONAL FINANCING OF UP TO EUR 10 MILLION THROUGH CONVERTIBLE NOTES WITH SHARE SUBSCRIPTION WARRANTS ATTACHED TO FINANCE FURTHER CLINICAL DEVELOPMENT OF NOX-A12 | | | |
| 2017, April 30 | NOXXON Pharma N.V. reports 2016 financial results and announces advanced discussions regarding a convertible bond financing | | | |
| 2017, February 10 | NOXXON Pharma announces experienced industry cancer clinician Dr. Jarl Ulf Jungnelius to serve as NOXXON CMO | | | |
| 2017, January 06 | Half-yearly report on the liquidity contract with INVEST securities | | | |
| 2017, January 04 | NOXXON PHARMA licenses and assigns preclinical Spiegelmer programs to APTARION | | | |
| 2016, December 15 | NOXXON Pharma signs clinical immuno-oncology collaboration agreement with MSD to study NOX-A12 combined with Keytruda (pembrolizumab) in pancreatic and colorectal cancer | | | |
| 2016, December 05 | NOXXON Pharma announces new preclinical data showing synergy of lead compound NOX-A12 with natural killer (NK) Cell mediated therapies | | | |
| 2016, October 31 | NOXXON releases its interim 2016 results | | | |
| 2016, October 24 | NOXXON Pharma announces the implementation of a liquidity contract with invest securities | | | |
| 2016, October 10 | NOXXON Pharma demonstrates synergies between NOX-A12 and therapies working through T cells or NK cells | | | |
| 2016, September 28 | NOXXON Pharma NV lists its shares on Alternext Paris | | | |
| 2016, January 20 | NOXXON Pharma hosts key opinion leader symposium | | ||
| 2015, July 14 | NOXXON appoints Aram Mangasarian as CEO | | | |
| 2015, May 29 | First Data from NOXXONs NOX-H94 (Lexaptepid Pegol) Clinical Trial in ESA-Hyporesponsive Dialysis Patients Reported at ERA-EDTA Conference | | | |
| 2015, April 23 | Nature Communications Publications on the First X-ray Crystal Structures of Spiegelmers Bound to Protein Targets | | | |
| 2014, December 10 | New Addition to NOXXON Supervisory Board Brings Significant US Public Market Expertise | | | |
| 2014, December 05 | Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in MM and CLL at 2014 American Society of Hematology (ASH) Conference | | | |
| 2014, September 26 | Cell Reports Publication on the Mechanism of Action of NOXXONs Anti-SDF-1 Spiegelmer Olaptesed Pegol (NOX-A12) in Preclinical Multiple Myeloma Models | | | |
| 2014, September 23 | NOXXON Spiegelmer receives FDA Orphan Drug Designation for Glioblastoma Treatment | | | |
| 2014, September 18 | NOXXON Pharma Expands Management Team by Appointing Don Munoz as Chief Financial Officer | | | |
| 2014, September 04 | Two Presentations at International Conferences of Preclinical Data on NOXXON's anti-C5a Spiegelmer, a Potential Drug in Pneumococcal Pneumonia-Induced Sepsis | | | |
| 2014, July 31 | NOXXON Initiates Phase IIa Study of Anti-Hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94) in Dialysis Patients with EPO-hyporesponsive Anemia | | | |
| 2014, June 13 | NOXXON presents Updates on Phase II Studies with Olaptesed Pegol (NOX-A12) in CLL and MM and Lexaptepid Pegol (NOX H94) in Anemic Cancer Patients | | | |
| 2014, June 02 | NOXXONs Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference | | | |
| 2014, April 08 | Anti-Hepcidin Spiegelmer Lexaptepid Pegol Increases Hemoglobin in Subset of Anemic Patients in Pilot Phase IIa Study | | | |
| 2014, April 04 | NOXXON presents Positive Results from Emapticap Pegol Phase IIa Diabetic Nephropathy Study | | | |
| 2013, December 09 | NOXXON presenting at ASH 2013 | | | |
| 2013, July 24 | NOXXON Pharma Completes Patient Recruitment for Phase IIa Study in Diabetic Nephropathy | | | |
| 2012, December 04 | NOXXON Initiates Phase IIa of Anti-Hepcidin Spiegelmer NOX-H94 | | | |
| 2012, September 26 | NOXXON Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 in Second Oncology Indication: Multiple Myeloma | | | |
| 2012, July 11 | NOXXON Initiates Phase IIa of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 for Treatment of Chronic Lymphocytic Leukemia | | | |
| 2012, June 19 | NOXXON Initiates Phase IIa of Spiegelmer NOX-E36 for Treatment of Diabetic Nephropathy | | | |
| 2012, April 4 | NOXXONs NOX-A12 Delays Glioblastoma Recurrence in Preclinical Model | | | |
| 2012, January 6 | NOXXON to Present at 30th Annual J.P. Morgan Healthcare Conference | | | |
| 2011, December 12 | NOXXONs SDF-1 inhibitor NOX-A12 completes Phase I | | | |
| 2011, September 06 | NOXXON initiates Phase I of NOX-H94 for Anemia of Chronic Disease | | | |
| 2011, February 03 | NOXXON Expands Management Team | | | |
| 2010, October 12 | NOXXON Confirms Total Capital Raise of €35m | | | |
| 2010, September 22 | NOXXON initiates multiple dose phase I clinical trial of SDF-1 inhibitor NOX-A12 | | | |
| 2010, July 7 | NOXXON to initiate phase Ib clinical trial of MCP-1 inhibitor NOX-E36 | | | |
| 2010, June 28 | NOXXON Pharma AG announces management changes | | | |
| 2010, May 27 | NOXXON Pharma AG raises €33 million in Series D Round | | | |
| 2010, May 18 | NOXXON Pharma AG appoints Dr. Aram Mangasarian as Chief Business Officer | | | |
| 2010, May 3 | NOXXON Announces the Completion of the First-in-Human Clinical Trial with Spiegelmer NOX-A 12 | | | |
| 2009, December 3 | NOXXON Pharma AG Achieves Milestone in Partnership with Eli Lilly and Company | | | |
| 2009, November 2 | NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer NOX-A12 | | | |
| 2009, October 12 | NOXXON announces excellent preliminary phase I trial results for Spiegelmer NOX-E36 | | | |
| 2009, September 3 | NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer NOX-A12 | | | |
| 2009, June 8 | NOXXON Announces Initiation of First Clinical Trial with a Spiegelmer | | | |
| 2008, July 8 | NOXXON Pharma announces appointment of Lawrence E. Posner to its Board of Directors | | ||
| 2008, June 11 | NOXXON Pharma AG Announces Licensing and Discovery Collaboration with Eli Lilly ... | | | |
| 2008, April 7 | NOXXON Receives Research Grant from the Federal Ministry of Education and Research | | ||
| 2008, January 7 | NOXXON Pharma AG appoints Dr. Frank Morich as CEO | | ||
| 2007, November 9 | NOXXON announces alliance with Roche | | ||
| 2007, June 8 | NOXXON Pharma announces appointment of Dr. Walter Wenninger as Chairman of the Board | | ||
| 2007, May 3 | NOXXON Pharma closes Series C Round at Euro 37 million | | ||
| 2007, February 9 | NOXXON Pharma AG to present at Bio CEO & Investor Conference 2007 in New York | | ||
| 2006, November 3 | NOXXON Pharma AG to present at Bio-Europe in Duesseldorf, Germany | | ||
| 2006, November 3 | NOXXON Pharma AG to present at Rodman & Renshaw 8th Annual Healthcare Conference | | ||
| 2006, October 4 | NOXXON Pharma AG to present at Sachs Associates 6th Annual Biotech in Europe... | | ||
| 2006, May 12 | NOXXON Pharma AG to present at the Rodman & Renshaw 3rd Annual Global Healthcare... | | ||
| 2006, May 10 | Change of management at NOXXON Pharma AG | | ||
| 2006, March 23 | NOXXON Pharma AG announces global strategic alliance with Pfizer. NOX-B11... | | ||
| 2006, March 15 | NOXXON Pharma AG announces publication of positive animal data with its vasopressin | | ||
| 2006, March 13 | NOXXON Pharma AG to present at Sachs Associates’ 5th Annual North America Forum... | | ||
| 2006, February 13 | NOXXON Pharma AG to present at Bio CEO & Investor Conference 2006 in New York | | ||